Literature DB >> 17289822

Predictors of premature antidepressant discontinuation in functional gastrointestinal disorders.

Gregory S Sayuk1, Jill E Elwing, Patrick J Lustman, Ray E Clouse.   

Abstract

OBJECTIVES: To identify factors responsible for premature antidepressant discontinuation that would assist in designing management strategies for patients with functional gastrointestinal disorders. Antidepressants are being used increasingly to manage patients with functional gastrointestinal disorders; poor patient adherence to treatment regimens, particularly in the period shortly after antidepressant initiation, is common and interferes with success.
METHODS: Clinical records were reviewed from 172 outpatients who attended a university-based practice and who had been prescribed antidepressants to manage their functional gastrointestinal symptoms. Survival analysis methods were used to determine independent predictors of premature antidepressant discontinuation (within 6 months of initiation). Logistic regression analyses were used to see if the same predictors were responsible for side effects or poor treatment response.
RESULTS: Premature antidepressant discontinuation occurred in 41 (23.8%) subjects. Somatization features (state or trait) and history of depression or an anxiety disorder were the most significant predictors of premature discontinuation (p < or = .01 for each). Advancing age and female sex also were independent predictors (p < .05 for each). Somatization features and psychiatric illness were each linked to poor treatment response, whereas somatization features most consistently were associated with antidepressant side effects.
CONCLUSIONS: Failure to maintain treatment occurs in nearly a quarter of outpatients given antidepressants for functional gastrointestinal disorders. Somatization features and history of depression or anxiety most significantly interfered with treatment by predicting side effects, poor treatment response, and premature antidepressant discontinuation. Management algorithms should include specific strategies targeted at patients with these risk factors for poor treatment adherence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289822     DOI: 10.1097/PSY.0b013e318031391d

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  9 in total

1.  Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.

Authors:  Heba N Iskandar; Benjamin Cassell; Navya Kanuri; C Prakash Gyawali; Alexandra Gutierrez; Themistocles Dassopoulos; Matthew A Ciorba; Gregory S Sayuk
Journal:  J Clin Gastroenterol       Date:  2014 May-Jun       Impact factor: 3.062

2.  Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome.

Authors:  H Henry Lai; Carol S North; Gerald L Andriole; Gregory S Sayuk; Barry A Hong
Journal:  J Urol       Date:  2012-04-12       Impact factor: 7.450

3.  Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients.

Authors:  Benjamin Cassell; C Prakash Gyawali; Vladimir M Kushnir; Britt M Gott; Billy D Nix; Gregory S Sayuk
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

4.  Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study.

Authors:  Victoria P Y Tan; Tin K Cheung; Wai M Wong; Roberta Pang; Benjamin C Y Wong
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

5.  Urological symptoms in a subset of patients with urological chronic pelvic pain syndrome and a polysymptomatic, polysyndromic pattern of presentation.

Authors:  H Henry Lai; Carol S North; Gerald L Andriole; Lori Cupps; David Song; Timothy J Ness; Barry A Hong
Journal:  J Urol       Date:  2013-12-19       Impact factor: 7.450

6.  Sensory neuromodulators in functional nausea and vomiting: predictors of response.

Authors:  Amit Patel; Gregory S Sayuk; Vladimir M Kushnir; C Prakash Gyawali
Journal:  Postgrad Med J       Date:  2012-10-30       Impact factor: 2.401

7.  History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study.

Authors:  David M Marks; Changsu Han; Stan Krulewicz; Chi-Un Pae; Kathleen Peindl; Ashwin A Patkar; Prakash S Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

8.  Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder.

Authors:  Juliana Belo Diniz; Dante Marino Malavazzi; Victor Fossaluza; Cristina Belotto-Silva; Sonia Borcato; Izabel Pimentel; Euripedes Constantino Miguel; Roseli Gedanke Shavitt
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.

Authors:  Darren M Brenner; Gregory S Sayuk; Catherine R Gutman; Esther Jo; Steven J R Elmes; Louis W C Liu; Brooks D Cash
Journal:  Am J Gastroenterol       Date:  2019-09       Impact factor: 10.864

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.